^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Positive Breast Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    AiRuiKang (dalpiciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A single-arm, double-cohort, prospective, open-label, phase II exploratory study evaluating dalpiciclib combined with pyrotinib maleate in first-line treatment of HER2+ advanced breast cancer

    Excerpt:
    ...Type of patient: (1) Cohort A: All patients were diagnosed with estrogen receptor (ER) positive (>10%) and/or progesterone receptor (PR) positive (>1%), HER2 receptor positive invasive breast cancer. ...
    Trial ID:
    ChiCTR2200058979
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).

    Published date:
    05/25/2023
    Excerpt:
    ER+/HER2+ MBC Pts eligible for first- or second-line treatment were enrolled to receive dalpiciclib combined with pyrotinib and ET (letrozole or fulvestrant determined by physician’s choice)….The ORR was 68.1% (32/47) and disease control rate was 100% (47/47)....The chemotherapy-sparing regimens showed significant anti-tumor activity for ER+/HER2+ MBC pts in the front-line setting.
    Secondary therapy:
    fulvestrant; letrozole
    DOI:
    10.1200/JCO.2023.41.16_suppl.1046
    Trial ID:
    PLEASURABLE